monoclonal antibody development

AdvantiGen Biosciences is expanding the landscape of Immuno-Oncology by unveiling sialic-acid-binding immunoglobulin-like lectin 5 (Siglec-5) as a novel target on activated T-cells for cancer immunotherapy. The company capitalizes on its expertise in monoclonal antibodies (mAbs) and NIRID (Near InfraRed Identification and Detection) to develop therapeutics and complementary biomarkers for pre-clinical and clinical patient selection and stratification.

biomarker developmentimmuno-oncology researchNear InfraRed Identification and Detection (NIRID)

Precision Antibody, a brand of A&G Pharmaceutical Inc., provides custom antibody development services with over 20 years of experience. The company develops mouse and rat monoclonal antibodies, fully human monoclonal antibodies, humanized antibodies, and polyclonal antibodies, and offers antibody production, purification, and characterization for pharmaceutical, biotech, academic, and federal laboratory clients.

antibody characterizationantibody humanizationantibody productionantibody purificationconjugationcustom antibody developmentcustom EIAepitope mappingflow based assaysIHCinternalization assaysmammalian cell bankingneutralization assaysOctet and Biacore binding analysispolyclonal antibody developmentrecombinant IgG expressionVH/VL sequencing

Allterum Therapeutics is an early-stage biotechnology company developing precision oncology and inflammation therapeutics. Its lead program, 4A10, is an anti-CD127 monoclonal antibody targeting the CD127 pathway (IL-7 receptor complex) for relapsed leukemia, acute lymphoblastic leukemia, B-cell malignancies, lymphomas, and CD127-expressing solid tumors. The 4A10 antibody was developed at the National Cancer Institute and licensed exclusively to Fannin; Allterum is a Fannin portfolio company.

clinical developmentdrug developmentpreclinical studiestranslational science

Amplifyer Bio is developing priming agents to improve liquid biopsy. Its first priming agent, AMP-001, is a monoclonal antibody that binds cfDNA, shielding it from clearance to transiently boost circulating DNA and improve the performance of liquid biopsy tests for applications such as disease monitoring, therapy selection, MRD, and early detection. The company is based in Cambridge, Massachusetts.

liquid biopsy enhancement

Ansh Labs is a developer and manufacturer of immunoassay reagent test kits used to advance target discovery, therapeutic development, biomedical research, and clinical diagnostics. The company serves life science researchers, physician researchers, hospitals, commercial laboratories, and public health agencies, and its products support research in reproductive function, pregnancy, central nervous system, atherosclerotic cardiovascular disease, and oncology. Ansh Labs is now part of the VION Biosciences family of companies.

antibody development and screeningassay developmentassay optimizationassay validationCLIAELISAimmunoassay developmentimmunofluorescenceimmunohistochemistryluminogenic microplateneutralizing antibodyWestern blot

Antibodies Incorporated is a manufacturer and distributor of monoclonal and polyclonal antibodies, diagnostic reagents, and diagnostic kits, and a developer and practitioner of immunoassays. The company states it has served the scientific community since 1962 and brings together brands including NeuroMab, Aves Labs, PhosphoSolutions, ImmunoChemistry Technologies, and Biosensis. It operates under a Quality Management System and is ISO 13485 certified.

adenovirus productionanimal housingantibody conjugationantibody purificationcontract manufacturingcustom antibody developmentcustom buffer manufacturingcustom peptide synthesisELISA/immunoassay developmenthybridoma sequencinglyophilizationphosphospecific antibody developmentplate coatingpolyclonal antibody developmentrecombinant antibody development

Antidote Therapeutics is a science-driven biopharmaceutical company developing first-in-class nicotine-blocking therapies to treat diseases caused or worsened by nicotine. Its proprietary treatments target rare vascular diseases and addiction, including a fully human anti-nicotine monoclonal antibody. Initial indications include orphan vascular diseases in smokers such as Buerger's Disease and Critical Limb Ischemia.

clinical research collaborationdrug developmentdrug discoveryimmunotherapeutic approaches

Bectas Therapeutics is a preclinical-stage biotech company developing monoclonal antibody therapies for cancer, accompanied by biomarkers to identify patients who will most benefit from each therapeutic antibody. Its programs combine monoclonal antibodies targeting secondary immune checkpoints that regulate myeloid-dependent immune suppression with patient-selection biomarkers based on insights from human patients. The company was awarded a $2.75M product development seed grant from the Cancer Prevention Research Institute of Texas (CPRIT) to support pre

biomarker developmentprecision oncologypre-clinical development

ChemMedImmune Inc. is a biopharmaceutical company whose mission is to develop immunotherapeutic agents for the treatment of human cancer. Its pipeline includes OPN monoclonal antibodies for colorectal and pancreatic cancer immunotherapy and IFNA2-LNP01, a cationic lipid nanoparticle-encapsulated IFNα2-encoding mini-plasmid DNA for treatment of patients with lung metastases.

immunotherapy developmentlipid nanoparticle drug development

Gamma Biotherapeutics is a private, clinical-stage biotechnology company discovering and developing therapeutics that help the immune system fight cancer. Its lead program M3T01, a FasL-neutralizing monoclonal antibody, is advancing through a Phase 1 first-in-human clinical trial in patients with advanced solid tumors at Providence Cancer Institute in Portland, Oregon.

clinical developmentclinical trialsdrug discovery

Immunartes is a biotechnology company developing therapies that neutralize Staphylococcus aureus immune evasion to restore host defense and prevent serious S. aureus disease. Its platform targets the immune-evasion pathway and supports coordinated vaccine and monoclonal antibody (mAb) programs aimed at prevention, currently in preclinical discovery and IND-enabling stages.

animal modelsantibody characterizationpreclinical researchtranslational immunologyvaccine antigen evaluationvaccine development

Innovative NeuroTechnologies, Inc. (INT) is a development-stage biotechnology company operating in a virtual mode that is pursuing biologically-based, disease-modifying therapeutic solutions for neurodegenerative disorders known as tauopathies, including Alzheimer's disease, frontotemporal dementia, chronic traumatic encephalopathy, progressive supranuclear palsy, and corticobasal degeneration. INT is advancing monoclonal antibody candidates against key epitopes of Tau toward Phase I clinical trials as prospective passive immunotherapies.

biotechnology research and developmentrecombinant AAV vector developmenttherapeutic development for tauopathies

Invivyd is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases. By pairing state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering techniques, it develops a pipeline of product candidates for prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. It deploys a proprietary integrated technology platform to create best-in-class antibodies.

antibody engineeringpredictive modelingviral surveillance